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Abstract 
Humans have long appreciated silk for its lustrous appeal and remarkable physical 
properties yet as we unravel the mysteries of silk, it becomes clear that this outstanding 
biopolymer is more than a high-tech fiber. This review provides a critical but detailed 
insight into the biomedical use of silk. This journey begins with a historical perspective 
of silk and its uses, including the long desire to reverse engineer silk. Selected silk 
structure-function relationships are then examined to appreciate past and current silk 
challenges. From this, biocompatibility and biodegradation is reviewed with a specific 
focus of silk performance in humans. The current clinical uses of silk (e.g., sutures, 
surgical meshes and fabrics) are discussed, as well as clinical trials (e.g., wound healing, 
tissue engineering) and emerging biomedical applications of silk across selected formats, 
such as silk solution, films, scaffolds, electron spun materials, hydrogels, and particles. 
The journey finishes with a look at the roadmap of next-generation recombinant silks, 
especially the development pipeline of this new industry for clinical use.  
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1. Prologue 
Before we begin to define the current state of the art surrounding the field of silk-based 
biomaterials for (bio)medical use and look toward their future, we feel it is important to 
spend some time considering the motivation of the research and the history of the 
material that has led us to the present day.  
 
The issue of motivation for studies in the field of silk research is generally divided into 
bottom-up, curiosity-driven fundamental research and top-down, challenge-based 
activities.  
 
Fundamental silk research hinges on the question, ÒWhat can we learn from nature?Ó This 
is clearly a wider topic than silk itself, but the overall approach helps frame scholarly 
activities in the area. We certainly have more to learn beyond understanding the silk fiber 
itself, and dozens of cross-disciplinary researchers worldwide are using both simulation 
and experimentation [1] to make concerted efforts to understand the evolution [2], 
processing [3], and performance of silk [4], from the molecule [5] to the material.[6] 
However, as we broaden our interpretive horizons, we must remember that silks are 
biological materials, and thus are defined by their biology, before we attempt to transfer 
this knowledge to biomaterials, which are defined through their application.  
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2. Introduction 
For the purpose of this review, we use the term silk to refer to protein-based fiber-
forming materials spun by living organisms. We also include in our terminology silk-
inspired proteins produced by recombinant approaches.  
 
When studying silks, one must always appreciate that the results derived from testing any 
naturally obtained biological material are a product of both Nature (its evolution) and 
nurture (its environment), with the latter typically constraining the property space of the 
former (although exceptions exist [4a, 7]). 
 
Evolutionarily speaking, the biological definition of silks is that they are structural 
proteins that are spun into fibers for use outside the body [4a, 8]. In the wild, silks have 
undergone over 400 million years of Òresearch and developmentÓ via natural selection, 
and they now present a plethora of solutions to biological challenges that range from 
predation (spider webs) to housing (honey bees and wasps) and protection (silkworm 
cocoons).[4a, 8] The ubiquity and widespread use of silk is a clear testament to its success, 
especially as it has arisen numerous times in independent convergent evolutionary 
events.[2c] Hence, looking at how silk materials have evolved can not only determine their 
performance in the present but can also unravel common design criteria and the 
molecular ÒblueprintsÓ for high performance biological materials.[4a, 9]  
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In unraveling the properties of silk, we have also begun to address common 
misconceptions regarding biological materials and their potential for industrial 
application. These are often tarred with a brush of sample variability suggesting that they 
are unsuitable for engineering or medical applications where consistency is key. 
However, recent studies now show that the variation previously observed is typically a 
manifestation of a silkÕs exquisite responsiveness to its surroundings (making silks 
incredibly ÒsmartÓ materials).[4d, 7a, 10] Yet for the uninitiated researcher this can 
sometimes become unwanted variation if the they fail to ensure consistent sample 
preparation or testing environments. Hence, biological diversity and plasticity offer 
several important lessons for those wishing to make the best use of silk for their own 
applications.  
 
At the other end of the spectrum is the widely held belief that biological materials 
automatically qualify as ÒbiocompatibleÓ materials. While these materials, including 
many silks, are often biocompatible, simply labeling silk as ÒbiocompatibleÓ without 
context specific biocompatibility testing and critical assessment of the available evidence 
is neither scientifically rigorous nor in the best interest of the field or, ultimately, patients. 
This mindset also permeates into the assumption that all natural materials are ÒgreenÓ 
which without appropriate and carefully considered environmental analysis, the 
ubiquitous use of the phrase ultimately detracts from the potential impact of these 
materials when such claims are shown to be valid.  
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Once we move past our prejudices, we can look forward and at the interface of 
fundamental and challenge-based activities sits biomimetics. This specifically looks to 
nature to reveal concepts, processes, and systems that can be applied to solve human 
challenges.[11] While the term ÒbiomimeticsÓ was only coined by American biophysicist 
Otto Schmitt in the latter half of the 20th century [11], humans have been looking to 
translate silkÕs natural utility for their own use for millennia.[12] The simplest, most 
primitive forms of mimicry are examples of imitation of the spiderÕs use of silk to catch 
prey, as seen in the Australian aboriginesÕ use of spider silk as fishing lines and New 
Guinean nativesÕ development of fishing nets and bags.[13] However, the biological 
diversity of silk soon inspired humans to adapt silk for their own needs (e.g. [14]), 
extending the silk phenotype beyond its natural remit. Some of the first examples were 
the use of silks medicinally by ancient Greeks and Romans, who bundled up spider silk to 
treat wounds (Figure 1).[13] This was even noted by ShakespeareÕs character, Nick 
Bottom, in A Midsummer NightÕs Dream, who says, ÒI shall desire you of more 
acquaintance, good master cobweb. If I cut my finger, I shall make bold of you.Ó 
(3.1.9.100-101).  
 
 
However, the above examples describe the use of silk in its unprocessed, natural state. A 
step forward in the utilitarian evolution of silk came about with the realization that silk 
could be readily reprocessed into different forms. This was first performed at the 
macroscale by unwinding fibers from the non-woven composite cocoons of the silkworm 
Bombyx mori to create textiles. This skill originated in China, and direct archeological 
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evidence confirms human interactions with silkworm silk originating from the Neolithic 
period of the 4th millennia BC, with the discovery of examples of cut cocoons and 
rudimentary looms at numerous archeological sites.[15] Further archeological evidence 
suggests that the Indus Valley civilization (in what is now Northern Pakistan) was also 
developing silk materials based on Antheraea silk. Therefore, sericultureÑthe act of 
rearing silkworms specifically for their silkÑcan be estimated to have spread across 
South Asia from 5,000Ñ2,000 BC.[16]  
 
Textiles produced from silk were truly a disruptive product, as they required both a 
unique material and highly sophisticated processing (programmable looms for weaving 
that were, in essence, the progenitor of modern computing).[17] As such, silk textiles were 
sufficiently valuable to become a formal currency for Chinese soldiers at the edges of the 
empire and were used to barter with the locals for goods.[15] Nevertheless, silk production 
remained a closely guarded secret within the Chinese empire for several thousand years, 
and when asked, traders would say it was Òderived from the wool of sheep sprinkled with 
water and exposed to sunshineÓ. However, this product monopoly could not go 
unchallenged for long, and the establishment of trade routes (the Òsilk roadsÓ), and the 
apocryphal industrial espionage that ensued, made silk technology available throughout 
the world. As a result, Bombyx mori silk has developed hand in hand with humans, 
through domestication and artificial selection of the moths for over 4,000 years.[15] This 
extensive history is a testament to the success and suitability of this animal for large-scale 
industrial agricultural development, as ~980 billion animals are raised each year to 
produce ~400 megatonnes of commercial silk.[18] 
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Across millennia, silk has been a luxury item for the elite. However, Claudius Galenus of 
Pergamon (c. 131 Ð c. 211 AD) was the first to document a potential medical application 
of the silk thread. Galenus gained a reputation for treating gladiators whose tendons were 
severed in hand-to-hand combat and noted in his book De Methodo Medendi (150 AD) 
the use of several materials as sutures, including linen. He writes, Òin many places under 
Roman rule you can obtain silk, especially in large cities where there are many wealthy 
women. If there is no such opportunity, choose from the material where you were living 
the least putrescible such as thin catgut.Ó GalenusÕs teaching persisted for centuries after 
his death but was eventually lost.[19] The war surgeon Ambroise Par (1510 Ð 1590) 
avoided cauterizing open wounds with boiling oil and reverted to using vascular ligatures 
made of silk or fine linen strips. However, only in 1869 did Joseph Lister introduce the 
first sterile silk suture into clinical practice.[19]  
 
Throughout history, several alternative sources for textile silk beyond the domesticated 
silkworm have been sought, from the wild silkworms of India and Africa [20] to the more 
esoteric source represented by spider silk. The quest to commercialize spider silk, due to 
its favorable mechanical properties, seemingly began with the inventions of Abb Ramon 
de Termeyer in the 18th Century for his reeling device.[21] Over the years, these inventions 
were followed by others, such as those of the Civil War surgeon Burt G. Wilder.[22] The 
most successful attempts are probably those made by the Madagascan spider silk 
industry, which has produced, to date, only a handful of items destined for the elite.[23] 
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Yet, while producing arguably mechanically superior materials compared to those made 
of silkworm silk, none of these endeavors were ultimately found to be scalable.  
 
Hence, given the coveted nature of silk, the fact that industrialists wished to replicate it 
may come as no surprise. In fact, nearly every single industrial fiber produced in the 
latter half of the 19th and throughout the 20th century, from rayon to nylon to Kevlar¨, 
has been developed in the hope that it would provide a suitable alternative to silk.[24] 
Nevertheless, even after 150 years of concerted research and development, and although 
replication of the properties and performance of silkworm silk is now possible, similar 
success with spider silk, and specifically dragline silk, remains elusive. A complete 
overview of the history, progress, and trends in artificial silk spinning from a fiber 
performance perspective is available in a recent review that comprehensively covers this 
topic.[24] 
 
Fortunately, the attempts to replicate various silks resulted in several distinctly important 
innovations that led the biomaterials field to consider silk as more than just a fiber.[12] 
Akin to the Ancient Chinese realizing that a silkworm cocoon can be unspun, early 
attempts at creating artificial silk led to the conclusion that the silk fiber itself could be 
ÒunspunÓ back into a processable protein feedstock, which could then be solidified into a 
variety of forms. According to the original patents, this finding was largely motivated by 
a need to utilize the waste streams from the industry[25], as the last tens to a hundred 
meters of silk from a cocoon could not be unraveled. (Today, this would be labelled an 
exercise in sustainability.) 
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To the best of our knowledge, the first attempt to create an artificial silk feedstock 
appeared at the turn of the 20th Century, 110 years ago. It began with the work of 
Baumann and Diesser, who proposed the dissolution of whole silk glands in formic 
acid.[26] In subsequent years, a notable race began between Japanese and German 
researchers in the 1920s, with patents granted in 1924-7[25a, 27] and 1928 [28], respectively, 
for the successful dissolution (and respinning) of artificial fibers using ZnCl2, Mg(NO3)2, 
and orthophosphoric acid as the main chaotropic agents. However, not until the 1930s did 
todayÕs familiar degumming using Na2CO3 
[29] and dissolution in LiBr appear.[25b] The 
latter report clearly noted the potential of silk regeneration/reconstitution: ÒThese 
solutions containing, if at all, only a small amount of salt, may be used in the known 
manner to produce artificial articles, such as fibers, films, or plastic masses.Ó  
 
Beyond the replication of silk fibers for textile use, these feedstocks were originally 
intended for reprocessing into solid form to harness silkÕs excellent insulating 
properties.[25b] and enable the casting of films (to make fabrics water and air impermeable 
[30]). This was mainly because naturally derived materials were still superior in many 
aspects when compared to those arising from the burgeoning field of industrial 
polymers.[31]  
 
Interestingly, nearly three decades passed before the first biomedical use for a 
regenerated silk was reported in the patent literature. In the 1960s, Boch and Messores, of 
Ethicon Inc. (NJ, USA), were the first to propose the use of a LiSCN/LiBr reconstituted 
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silk as a replacement for the standard wax coating used on silk sutures to reduce their 
limpness, fraying, and unwanted capillary action.[32] In the following years, while 
developments continued in the suture field, another two decades passed before the first 
examples of non-fibrous silk-based biomaterial patents were reported. In 1986, a silk 
fibroin:fibrinogen glue, based on the ÒstandardÓ LiBr reconstitution approach, was 
developed by a Japanese firm.[33] This was followed by the first patent for a silk based 
porous scaffold in 1987, again from Japan, produced from a freeze-dried native silk 
solution (i.e., silk extracted directly from the silk gland).[34] The 1990s saw more patent 
applications from Japan, including powdered silk for wound dressings[35], reconstituted 
silk films and molded gels for skin, blood vessel, and corneal coatings [36], and colloidal 
silk for consumption in medicine.[37] However, in the 2000s, an explosion occurred in the 
USA in research and commercialization activity around this area with the emergence of 
large patent families (>100) focused on the future medical exploitation of these 
materials.[38]  
 
In summary, looking back, the ability to unspin silk, and thereby reconstitute it, has been 
a monumentally disruptive development in the field. It represents a platform technology 
for the development of biomimetic structures that are built with silk but are not built to 
replicate silk. While gaps still undoubtedly exist in our knowledge surrounding the 
process of reconstitution and how this affects the integrity and application of the silk 
proteins undergoing it [39], the unspinning process has been widely adopted throughout 
the biomaterials field, as perhaps best evidenced by the impact of the landmark review of 
Altman [40] and the protocol of Rockwood [41], which leads us in the present day.   
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3. Silk: Hierarchical and crystal structures 
The fundamental building blocks of the silk biopolymer are amino acids that, through 
their sequence specificity and subsequent secondary, tertiary, and quaternary structures, 
govern the proteinÕs overall function. In nature, silk and silk-like proteins are made by 
several organisms such as spiders, silkworms, scorpions, mussels bees and ants. 
However, the silk fibroins and silk-like proteins of each organism exhibit different 
physical and biological characters due to their different amino acid sequences, spinning 
conditions, and hierarchical structures.[7b, 42] The hierarchical structures of silk proteins 
vary among silk types.[42a, 43] Silk proteins produced by spiders and insects are referred to 
as silk spidroin and silk fibroin, respectively. The term Òsilk fibroinÓ is commonly used to 
differentiate ÒvirginÓ silk (silk filament still encased by sericin) or silk cocoons (i.e., the 
sericin-coated silk thread arranged into a cocoon) from purified silk (i.e., degummed; see 
section 6). For the purpose of this review, we will use the term silk fibroin to refer to 
degummed (Bombyx mori) silk unless otherwise stated.  
 
 
As discussed in the previous section, the silk fibroin of the domesticated silkworm 
(Bombyx mori) is the most well studied silk for biomedical applications due to its 
established supply chain, abundance, and clinical track record. The Bombyx mori protein 
fiber is a composite material comprising a semi-crystalline silk core (i.e. silk fibroin), 
which is mainly responsible for the load-bearing capacity, and an outer layer of sericin, 
which functions as a gumming agent.[44] However, emerging evidence suggests that 
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sericin also inhibits the premature conversion of soluble silk (silk I) into β-sheetÐrich 
silk.[45]  
 
The Bombyx mori silk protein (i.e. silk fibroin) is very large and can be subdivided into 
light (approximately 26 kDa) and heavy (approximately 391 kDa) chains that are linked 
by a single disulfide bond at the C-terminus [46] (Figure 2). The C- and N-terminal 
capping sequences are completely non-repeating amino acid residues. The mechanical 
properties of silk fibroin arise due to the block copolymer-like arrangement of the silk 
heavy chain, which contains 11 short hydrophilic regions typically 31 amino acid long 
and 12 hydrophobic blocks that account for 94% of the silk heavy chain. These 
hydrophobic blocks contain predominately glycine-X (GX) repeats, where X is alanine 
(A) (65%), serine (S) (23%), or tyrosine (Y) (9%).[46a] These GX blocks can be broadly 
classified into three groups: (i) a highly repetitive GAGAGS sequence that contributes to 
the bulk of the crystalline regions and is typically found at the beginning of each motive, 
(ii) a relative less repetitive sequence containing hydrophobic and/or aromatic residues, 
namely, GAGAGY, GAGAGV, and GAGAGVGY, which form semi-crystalline regions, 
and (iii) motifs similar to (i) except for the presence of an AAS motif, which typically 
exists at the C-terminus of each motif and may play a role for sheet-breaking.[47] Bombyx 
mori silk fibroin lacks the tripeptide sequence arginine, glycine, and glutamic acid (RGD) 
that is typically exploited by cells to mediated cell-substrate attachment via integrin 
engagement; however, the N terminal of the silk heavy chain contains a fibroblast 
growth-promoting peptide.[48] Nevertheless, a sequence specificity exists between 
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different silkworm silks; for example, the Indian non-mulberry tasar silkworm 
(Antheraea mylitta) contains RGD sequences that are absent in Bombyx mori silk. 
 
 
 
Spider dragline silk, one of the toughest material known to humankind, is composed of a 
skin layer and a bundle of microfibrils (Figure 1).[5b, 54] The microfibrils are composed of 
aligned granules, and their silk molecules form an amorphous phase and β-sheetÐrich 
crystalline regions.[5b] In both spider and silkworm silk fibers, the aligned β-sheet 
structure provides crosslinks between the β-sheet domains embedded in an amorphous 
matrix that consists of less orderly structures in the form of random coils, helices, and β-
turns.[55] These β-sheet crystals are critical structures in the hierarchical structures of silk 
fibers, because they play an essential role as crosslinking points and realize the stiffness, 
strength, toughness and characteristic deformation behaviors.[55a, 55b, 56]  
 
The amino acid sequences that form the β-sheet are 7Ð9mer alanine sequences for 
Nephila clavipes dragline silk and GAGAGS for Bombyx mori [57], whereas other 
silkworm silk species use polyalanine sequences to form the β-sheet structure.[6a] The 
influence of the number of alanine residues on the secondary structure and assembly 
behaviors of silk molecules has been studied using wide angle X-ray crystallography as 
well as solid-state NMR spectroscopy. Those data from X-ray and NMR analyses reveal 
that short poly(alanine) sequences, such as 6mers or shorter, form a packed rectangular 
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arrangement, while poly(alanine) sequences longer than 7mers pack in a staggered 
arrangement.[58] 
 
The β-sheet is the most fundamental secondary structure in silk-based (bio)materials. The 
predominant β-sheet structure plays a key role in stabilizing silk materials via physical 
cross-links, as the β-sheet behaves as a crosslinking point. Crystal structures of silk β-
sheets have been characterized using wide-angle X-ray analysis. The crystal structure of 
Bombyx mori silk fibre has a unit cell with the space group P21-C2
2 .[59] The crystal lattice 
of the Bombyx mori silk fiber reported by Marsh et al. had unit cell dimensions of a = 
9.40 , b = 9.20 , and c (fiber axis) = 6.97 , while Takahashi et al. reported cell 
dimensions of a = 9.38 , b = 9.49 , and c (fiber axis) = 6.98 .[59] The lattice of other 
silks, such as Antheraea yamamai (Japanese silk moth), has been characterized and 
reported by many groups [56b]. The unit cells contain four molecular chains, a pair of 
which symmetrically forms a β-sheet structure via hydrogen bonds. The up- and down-
molecular chains also alternate with each other in an antiparallel manner. Each silk has a 
different crystal lattice, which can be attributed to differences of the silk amino acid 
sequences. However, the relationship between the crystal lattices of different silks and the 
subsequent characteristics of silk fibroin as a biomaterial remains largely unexplored, 
despite the fact that crystallinity (i.e., the amount of crystalline region) affects the 
physical and biological properties of silk-based biomaterials.  
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4. Hydration State 
Silk and regenerated silk fibroin materials are expected to exhibit high toughness and 
ductility because of the excellent mechanical characters of spider (dragline) silks found in 
nature.[9, 60] However, in addition to sequence specificity, the hydration state of silk is 
critical for its performance.[61] For example, most native spider silks show significant 
fiber contraction when transitioned from a dry state to a high humidity environment. 
Exposure to humidity facilitates the rearrangement of the non-crystalline GPGXX 
sequence of orb web silks and the glycine-glycine-X 310 helices in non-orbicularian 
species (which lack the GPGXX sequence). This occurs due to disruption of hydrogen 
bonding by these sequences, which facilitates the transition from a parallel arrangement 
for the fiber axis to a lower energetic configuration that is accompanied by fiber 
shrinkage and thickening.[62] Thus, water is a key component that enables spiders to tailor 
the properties of their silks during spinning and for in situ web tightening (a phenomenon 
also known as ÒsupercontractionÓ).[62]  
 
In nature, silkworm cocoons and spider webs/draglines are tough structural materials that 
perform their function; for example, to capture prey in the spiderÕs web or to protect the 
developing moth from predators and infection [56b]. The mechanical robustness of the 
native silk fiber has been exploited by humans for biomedical applications both in pre-
clinical (e.g., [63]) and clinical trials (detailed below). For example, silk fibroin scaffolds 
proposed for bone repair have shown a high compressive strength of approximately 13 
MPa when reinforced with Bombyx mori silk fibers.[63] A similar approach has been taken 
to enhance the mechanical properties of Bombyx mori silk hydrogels for cartilage tissue 
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engineering.[64] Recently, a high relative humidity of >97% was found to cause a 
dramatic increase in the toughness and crystallinity of silk films.[6a] This finding 
exemplifies how an appropriate hydration of silk molecules and materials can achieve 
crystallization and plasticization simultaneously, resulting in a high-strength and tough 
silk material.  
 
5. Silk for tissue engineering and drug delivery Ð expectations, hopes, and the reality 
An excellent delivery system for bioactive molecules (e.g., small molecular weight drugs, 
peptides, proteins, etc.) must meet a number of requirements that include, but are not 
limited to: biocompatibility, biodegradability, mechanical robustness and durability, and 
amenability to processing under ambient aqueous conditions that preserve the bioactivity 
of the payload. Many of these requirements also apply for tissue engineering applications 
aimed at delivering or recruiting (endogenous) cells, although these silk constructs must 
also be able to provide cells with the necessary physical and biological cues to achieve 
the desired function.  
 
5.1 Silk biocompatibility 
The exact set of biocompatibility requirements is application specific, although many pre-
clinical studies simply cite that silk can meet all the necessary requirements, or they make 
reference to silk as a Òclinically approvedÓ biomaterial for use in humans. However, this 
ignores our appreciation that a universal biocompatibility does not exist: a material needs 
to be fit for its intended use [65] (as documented by dedicated biocompatibility studies); 
thus, its performance is context specific. The clinical approval of silk typically refers to 
  
18 
 
its load bearing applications; however, degummed Bombyx mori silk fibers processed into 
a knitted surgical mesh (SERI¨ Surgical Scaffold¨ manufactured by Sofregen Inc., 
Medford, MA, USA), silk sutures (coated with waxes, Ethicon Inc. and several other 
manufacturers), and silk garments to treat dermatological conditions are in wide use 
today in the clinical setting. Therefore, their performance in humans is becoming better 
documented in the literature [40, 66] and is accompanied by a cadre of clinicians with 
experience working with these silk materials.  
 
Dedicated biocompatibility assessment is critical when generating novel silk formats 
(e.g., (nano)particles, hydrogels, scaffolds, films, coatings, etc.) to address areas of unmet 
clinical need or when applying existing silk technologies to new indications. Any non-
autologous material will elicit an initial foreign body response that reflects the first steps 
of tissue repair.[67] Therefore, ensuring that the foreign body response is transient rather 
than chronic is a prerequisite to ensure that clinical endpoints can be met. Overall, 
biomaterial performance depends on the implantation site, size, geometry, surface 
topography, and physical characteristics.[67] A systematic literature review [68] examining 
the performance of silk constructs (e.g., vascular grafts, ligaments, and wound dressings 
for skin grafting) in small and large animal studies overwhelming showed that a variety 
of different Bombyx mori silk constructs performed well across the broad spectrum of 
indications and animal models.[68] Direct in vivo comparison of silk with commonly used 
natural (e.g., collagen) and synthetic (e.g., polycaprolactone, polylactic acid, poly[lactide-
co-glycolic acid]) biomaterials indicates that Bombyx mori silk fibroin is typically at least 
as good as these synthetic materials and often superior than other natural biopolymers.[68]  
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As new applications for silk emerge, appropriate biocompatibility studies must be 
performed to support these developments. For example, silk nanoparticles for anticancer 
drug delivery are typically designed for intravenous administration [69] and thus require 
hemocompatibility assessments because biological performance cannot be deduced by 
extrapolating results from macroscopic films [70] to nano-scale particles [71]. An initial 
proof of biocompatibility is a first step to translate silk technologies from the bench to the 
clinical setting. For example, regulatory frameworks imposed by the Pharmaceuticals and 
Medical Devices Agency Japan, the Food and Drug Administration (FDA, USA), the 
Medicines and Healthcare Products Regulatory Agency (UK), and the European 
Medicine Regulatory Agency (EU) for medical devices (e.g., Regulation (EU) 2017/745 
to obtain CE marking analogous to the Class III Premarket Approval/ 510(k) in the USA, 
and the Australian Register of Therapeutic Goods certificate of inclusion) stipulate that a 
biological safety assessment needs to be conducted first (by an ISO certified laboratory, 
in conjunction with a notified body) before progressing the device to first-in-man clinical 
assessment. Materials of animal or allogeneic origin need to fulfill additional safety 
requirements (e.g., absence of infectious agents such as retroviruses etc.) before use in 
humans. However, from a regulatory perspective, Bombyx mori silk is regarded as a non-
animal product (EU Council Directive 93/42/EEC, rule 17). 
 
Reports on the biocompatibility of silk in humans comes primarily from silk sutures 
(reviewed in [40]) that have been in use for several centuries [19] and from SERI Surgical 
Scaffold¨ that obtained 510(k) clearance by the FDA in 2008 and underwent a market 
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launch in 2013. Histological evidence of 69 breast tissue samples (by 60 patients) taken 
at stage 2 in patients undergoing two-stage breast reconstruction with SERI Surgical 
Scaffold¨ showed a mild inflammatory response in 59 patients, as confirmed by 
histology. This consisted of an infiltration of mostly macrophages and occasional 
multinucleated giant cells that phagocytosed the silk fibers, as well as occasional 
lymphocytes and, rarely, neutrophils or polymorphonuclear cells.[72] Ordered collagen 
deposition was observed, with minimal or no encapsulation of the silk surgical mesh. 
These clinical trial data [72] were similar to observations made in a sheep study.[73] 
However, one patient had a postoperative hematoma that led to mesh removal.[72]   
 
Synthetics are now the most widely used suture material, but silk sutures are still in 
demand for specialized applications where exquisite handling is of paramount importance 
(e.g., eye surgery). Silk sutures are strong, are easy to handle, lie flat on the tissue 
surface, and allow for secure knots. Adverse reactions to silk sutures are typically 
reported for virgin silk, where the silk filaments are still coated with sericin (and often 
with additional waxes or silicones).[40] There is an ongoing debate about the potential role 
of sericin in these adverse reactions. However, emerging evidence suggests that sericin 
on its own shows a low allergenic and immunogenic profile in mice; in fact, this profile is 
similar to that seen for silk fibroin or alginate.[74] These observations are supported by in 
vitro data with macrophages: extracted sericin from Bombyx mori silk cocoons showed 
no significant release of the inflammatory marker TNF-α; similar observations were 
made with silk fibroin.[75] However, extracted sericin in combination with bacterial 
lipopolysaccharide induced TNF-α release (but not for the silk fibroin group). 
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Furthermore, re-coating of silk fibroin with sericin showed no macrophage response, 
while virgin silk induced a high level of TNF-α release.[75] These data suggest that other 
leachable compound(s), or these compounds combined with sericin, may be responsible 
for the adverse clinical reactions reported for silk.[68, 75] For example, patients subjected to 
bilateral cataract surgery showed no suture reaction on the first eye but a severe reaction 
on the second eye when it was treated 6 to 3 months later. This suggested that these 
patients had undergone a sensitization toward virgin silk. Prompt removal of the 
offending silk suture resulted in significant clinical improvement.[76] Examining the 
clinical literature regarding silk sutures and identifying the exact cause of the adverse 
reaction is challenging because often little (or no) information is provided about the exact 
nature of the silk suture (e.g., virgin silk, type of coatings, etc.). Nonetheless, an allergic 
response to Bombyx mori virgin silk is documented for the occupational and domestic 
setting (reviewed in [77]). For example, exposure to virgin silk fibers and re-purposed silk 
waste (e.g., silk floss incorporated into rugs and bedding) has been linked to the 
development of asthma in silk weavers[78] and children[79], mounted by an IgG and IgE 
immune response.[80] Textile workers have an increased risk of developing chronic 
obstructive pulmonary disease, and this risk is highest in silk workers.[81]  
 
Complete and reproducible sericin removal from Bombyx mori silk (a.k.a. degumming) is 
an essential step in silk utilization. Clinically acceptable limits for residual sericin levels 
for marketed silk products have not been released into the public domain (note that SERI 
Surgical Scaffold¨ is described by the manufacturer as highly purified silk with ≥ 95% 
purity). Current evidence from both preclinical in vivo studies and clinical experience in 
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humans across a range of applications indicates that Bombyx mori silk fibroin is 
biocompatible, provided that all other contaminants are successfully removed.  
 
Sericin has traditionally been linked to the adverse effects reported for virgin silk 
(reviewed in [77]). However, over the past decade, sericin has emerged as an interesting 
biopolymer (reviewed in [82]), and dedicated biocompatibility studies are now showing 
encouraging results in relation to the allergenic and immunogenic profile of sericin (e.g., 
[74]). An increasing number of studies report the biomedical use of the biopolymer sericin. 
For example, the development of composite sericin/silicone nerve guides[83] or 
sericin/polyacrylamide hydrogels proposed for dermal repair[84]. Preliminary Phase I 
clinical trials using sericin composite wound dressings for split-thickness skin grafting 
are on going and the results are eagerly awaited (NCT01539980 and NCT02643680 
reported at www.ClinicalTrials.gov). 
 
5.2 Silk biodegradation 
Silk sutures are classified by regulatory agencies as non-biodegradable because 
regulatory guidelines expect a loss of most tensile strength within 60 days post 
implantation. Over this time scale, silk sutures do not lose their mechanical performance, 
as they require longer time frames to degrade in humans.[40] In patients undergoing two-
stage breast reconstruction, histological evidence of breast tissue samples taken from 60 
patients at stage 2 (median 152 days after initial scaffold implantation, range 74 to 357 
days) showed consistent SERI Surgical Scaffold¨ degradation (although this was not 
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quantified). The one exception was a patient that had a postoperative hematoma, which 
was accompanied by an apparent lack of silk degradation.[72]  
 
The silk protein is known to degrade in vitro and in vivo in response to proteolytic 
enzymes [68], as exemplified by studies with silk films (e.g., [85]) and porous silk scaffolds 
(e.g., [86]). Experience with SERI Surgical Scaffold¨ in a sheep model of two-stage 
breast reconstruction showed progressive degradation and vascularization of the silk 
mesh: at 1 month post implantation, tissue ingrowth and marked vascularization was 
evident; at 4 months, the mesh was no longer felt through the skin; and at 12 months, the 
mesh degradation and vascularization was scored as mild but with substantial silk loss 
that precluded mechanical testing of the remaining SERI Surgical Scaffold¨.[73] At 12 
months, the SERI Surgical Scaffold¨ had stimulated extensive type I collagen deposition 
and the resulting tissue was mechanically strong.[73] Clinical hernia repair in a horse 
showed incomplete SERI Surgical Scaffold¨ degradation at 2 years post implantation, 
but no hernia relapse.[87]  
 
The time scale for silk degradation depends on a number of factors, including, but not 
limited to: (i) the amount of material, (ii) gross morphology, (iii) silk secondary structure, 
(iv) silk treatment history, (v) mechanical environment, and (vi) implantation site (or 
final destination). The implantation site directly impacts the type of proteolytic enzyme 
encountered by the silk, because these enzymes vary between tissues, cells, and 
subcellular location.  
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Silk fibroin sequence alignment indicates a susceptibility to a number of proteases (e.g., 
protease XIV, α-chymotrypsin, proteinase K, papain, matrix metalloproteinases, 
collagenase etc.) [50, 88]). Nonetheless, predicting silk fibroin degradation simply based on 
the primary sequence is unreliable; for example, chymotrypsin has 434 cleavage sites in 
the silk heavy chain and 81 in the light chain, while protease XIV has 348 in the heavy 
chain and 41 in the light chain. Despite numerous cleavage sites, chymotrypsin treatment 
for 20 days had no quantifiable effect on silk fibroin, while protease XIV significantly 
degraded silk fibroin in vitro.[50] Papain, a cysteine protease enzyme that mimics the 
activity of lysosomal enzymes, has 26 cleavage sites in the silk heavy chain (albeit 
exclusively in the amorphous regions) and 15 in the light chain, and it caused significant 
silk fibroin degradation over 20 days but at a slower rate than protease XIV. Similar 
observations were made with isolated lysosomal enzyme preparations.[50]  
 
Overall, these studies exemplify that the structure beyond the primary sequence is of 
critical importance for silk degradation. The current working model supports the notion 
that, for Bombyx mori silk, degradation begins with the 11 hydrophilic amorphous 
segments in the silk heavy chain, as well as the C- and N-terminal and the silk light 
chain, which consist of completely non repeating amino acid sequences; this is then 
followed by degradation of the more crystalline sequences.[50, 60c, 88] The tightly packed 
crystalline domains are degraded last.[89] Furthermore, the silk format is a critical factor 
in determining degradation rates, as in vivo studies in rodent models indicated faster 
degradation for open silk structures than for tightly packed monolithic silk fibroin films 
(rank order: hydrogel > silk scaffold > monolithic film).[68]  
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Protease XIV is a useful model enzyme for studying silk degradation and for comparing 
with earlier studies. However, protease XIV is a non-mammalian enzyme cocktail, so it 
must not be used to deduce or predict biocompatibility performance. Silk, as a protein-
based biopolymer, is commonly considered to yield harmless biodegradation products; 
however, a more critical inspection of silk and its degradation products is timely. For 
example, silk fibrils have molecular-level similarity to amyloid fibrils [90], and they were 
also reported to enhance amyloidosis of amyloid protein through a mechanism based on 
cross-seeding effects.[91] However, when silk nano- and micro-fibrils were composed of 
β-sheets, which are known to affect various properties of silk fibers, they demonstrated 
no significant cytotoxicity toward in vitro neuronal cells. When the silk fibroin was 
degraded with chymotrypsin to yield mainly unordered soluble fragments with a low β-
strand content, the degradation products caused no significant amyloidosis. By contrast, 
significant cytotoxicity was observed when silk fibroin was degraded with protease XIV 
due to the formation of soluble β-sheet rich fragments [60c].  
 
Formation of β-amyloid structures is a concern because amyloid beta fibrils are a 
hallmark of AlzheimerÕs disease.[60c, 92] Preliminary studies in mice injected with self-
assembling silk fibroin hydrogels into the caudate putamen (striatum) showed no decline 
in cognitive function or animal behavior over the 6 week study period.[93]  
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6. Processing of silk cocoons Ð generating silk for biomedical use 
Unspinning the Bombyx mori silk cocoon and degumming to remove sericin, are two 
crucial steps that yield silk suitable for biomedical use. Sericin can be removed by 
enzymatic methods (i.e., digesting sericin but not silk) or chemical processing (e.g., 
alkaline treatment). The latter approach is widely used and typically involves boiling silk 
in sodium bicarbonate for 20 to 60 minutes.[41] Degumming times as short as 5 minutes 
are also sufficient to remove sericin while minimizing silk damage, which usually occurs 
due to cleavage of the disulfide bond between the silk heavy and lights chain and 
fragmentation of the amorphous silk sequences in the silk heavy chain, which results in 
polydispersed silk.[94] 
 
The degummed silk fibers can be fully reverse engineered by dissolving them in a high 
concentration chaotropic agent (for example, 9.3M lithium bromide) at 60 ¼C over several 
hours to dissemble the higher order silk structure. The resulting silk fibroin solution is 
then dialyzed extensively against water to yield an aqueous silk solution that is stable at 
room temperature for weeks and at 4¼C for several months.[41] When compared to native 
silk feedstock, this reverse engineered silk fibroin solution has a reduced solution 
conformation [95] and changed rheological properties.[39d]  
 
The reverse engineered aqueous silk fibroin solution is commonly used to generate novel 
silk formats; for example films, fibers, scaffolds, and (self-assembling) silk hydrogels, as 
well as (nano)particles and (nano)coatings, and these formats are often achieved using an 
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all aqueous processing under ambient conditions. These mild processing conditions are 
ideal for preserving the activity of biologics. 
 
7. Present routine clinical use of silk 
The silk surgical mesh SERI Surgical Scaffold¨, silk sutures, and silk clothing to treat 
dermatological conditions are the only available products in routine clinical use today. 
All these products are manufactured by unwinding Bombyx mori silk cocoons and 
working with the silk thread. The clinical performance of silk sutures, their adverse 
effects, and the developments and potential solutions to improve suture performance have 
been reviewed previously.[40]  
 
The SERI Surgical Scaffold¨ technology is based on work conducted by David Kaplan 
and colleagues at Tufts University, Medford, MA, USA.[96] The resulting patent portfolio 
and proprietary silk processing technologies formed the basis of the spinoff company, 
Serica Technologies Inc. (Medford, MA, USA). Serica Technologies Inc. was able to 
prove to the FDA that SERI Surgical Scaffold¨ was Òsubstantially equivalentÓ to 
existing surgical meshes and thus received 510(k) clearance to market the device. Serica 
Technologies Inc. was subsequently acquired by Allergan Inc., and the SERI Surgical 
Scaffold¨ became commercially available for soft tissue support and repair in 2013 and 
was since then acquired by Sofregen Medical Inc. (Medford, MA, USA). 
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The current SERI Surgical Scaffold¨ indications are for abdominal wall reconstruction 
[97] and investigational plastic surgery applications, including total body contouring, 
brachioplasty, abdominoplasty, mastopexy, and breast reconstruction (Table 1).  
 
 
The clinical performance of SERI Surgical Scaffold¨ has been reported in the literature, 
which includes open label clinical trials and case reports (Table 1). Many of these 
encouraging clinical studies have been sponsored by Allergan Inc. A few independent 
retrospective clinical reports of small patient cohorts are reporting side effects (e.g., poor 
scaffold integration, see Table 1, Figure 3), often requiring surgical removal of the 
mesh.[66b, 104-105] Therefore, some clinicians are abandoning the use of SERI Surgical 
Scaffold¨ in their clinical practices [104], and caution has been raised by others.[107] In 
2013, Allergan Inc. voluntary withdraw several SERI Surgical Scaffold¨ batches due to 
concerns about product sterility. How this might have affected the reported adverse 
events is not known. 
 
We are familiar with silk for the textile industry, although silk garments are also used 
clinically to treat dermatological conditions, especially atopic dermatitis [108] and acne 
vulgaris [109] (Table 2). Mechanical skin irritation by harsh, rough (e.g., wool) and short 
(e.g., cotton) textile fibers are thought to contribute to atopic dermatitis. Furthermore, the 
skin of atopic dermatitis patients is often colonized with Staphylococcus aureus and the 
extent of colonization correlates with the severity of the disease. Silk fibers are very long 
(up to 1,500 m) and smooth, so they minimize mechanical irritation when knitted into 
clothing. This silk clothing has been chemically modified to achieve antibacterial 
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properties with the aim of reducing Staphylococcus aureus colonization of the skin. 
Sericin-free silk has also been covalently functionalized with 3-trimethylsilylpropyl-
dimethyloctadecyl ammonium chloride (AEM 5700/5772; AEGISª), resulting in 
commercial products (e.g., DermaSilk¨) for the treatment of atopic dermatitis. These silk 
garments use highly purified silk to minimize the risk of contact dermatitis.[110]  
 
The silk garments are also knitted in a specific fashion to improve transpiration of sweat 
through the fabric (unlike everyday silk, which can worsen atopic dermatitis by trapping 
moisture). A randomized double-blind study in 30 patients with atopic dermatitis on both 
arms received an AEM 5700/5772 functionalized silk sleeve and a silk-only sleeve. 
Patients treated with the silk sleeve showed a rapid improvement within 2 weeks but 
remained similar until the end of the study. The contralateral arm treated with the AEM 
5700/5772 functionalized silk showed similar results at 2 weeks but reached a greater 
level of improvement over 4 weeks [108d]. Other clinical trials using AEM 5700/5772 
functionalized silk garments in small patient cohorts reported substantial improvements 
in skin conditions (Table 2). By contrast, a randomized, controlled, observer-blinded 
clinical trial in 300 children showed only a 3% reduction in skin infection compared to 
control and was therefore not regarded as providing a significant clinical benefit.[108e] 
Overall, these clinical trials are difficult to conduct, and the use of different silk garments 
(DermaSilk¨ and DreamSkin¨, see Table 2 for details) undermines the power of the 
study; therefore, these difficulties might result in underestimation of treatment effects due 
to objective primary outcome measures. Overall, improving these silk garments to 
maximize their clinical performance requires more research.   
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8. Clinical trials using silk 
 
The renewed interest in silk for biomedical use over the past 20 years has resulted in a 
number of clinical trials; however, historically, these data sets have been difficult to 
source. Since 2007, the FDA has mandated that drug and device manufacturers register 
clinical trials (www.ClinicTrials.gov) (Table 3).  
 
Silk-based biomaterials show particular promise for skin wound healing due to their 
hemostatic properties, low inflammatory potential, and permeability to oxygen and water, 
as well as their ability to function as a barrier to bacterial colonization (Table 3). Sidaiyi, 
a silk fibroin sponge attached to a silicone membrane, is a first generation wound 
dressing currently approved by the China Food and Drug Administration for clinical use 
in that country.[112] The Sidaiyi platform was first compared to silk fibroin films for 
wound healing applications in preclinical animal models, followed by a randomized, 
single blinded Phase I clinical trial. Silk films were made by casting an aqueous Bombyx 
mori silk fibroin solution in a mold and treating it at 65ûC and 90% relative humidity for 
100 minutes. The resulting 64.9 µm films were water-resistant (albeit their ability to bind 
a small amount of water that acts as a plasticizer) and formed an effective barrier against 
bacterial infection in vitro. The films were found biocompatible for their intended use 
according to ISO 10993 tests for the biological evaluation of medical devices. In a rabbit 
full-thickness wound healing model, healing was three days faster in wounds treated with 
silk films than in wounds treated with Suprathel, a polyurethane-based synthetic wound 
dressing, and seven days faster than in wounds treated with the Sidaiyi wound dressing or 
PBS treated controls (Figure 4). Silk-filmÐtreated wounds showed the development of an 
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organized epidermis by day 14 post-treatment and showed a mature and organized 
collagen matrix, hair follicles, and blood vessels histologically by day 21.[112] These 
results were further verified in a porcine full-thickness wound healing model prior to 
initiation of a Phase I clinical trial that ran from August 2013 to September 2014. This 
clinical trial enrolled 71 patients (36 randomly assigned to a silk film group and 35 to a 
Sidaiyi group). The silk-based wound dressings were used to cover donor sites following 
surgical harvesting of split-thickness skin grafts; healing was significantly faster in the 
silk film group than in the Sidaiyi wound dressing group and 100% of the wounds were 
healed by day 14 post injury in the silk film group. One case of inflammatory reaction to 
the silk film was noted but the exact etiology was not determined. No cases of wound 
exudation were observed, indicating that the silk films maintained a clean wound 
environment with suitable moisture levels. The films showed good adhesion to the wound 
surface and no changes of the wound dressing were required. As the wound healed, the 
silk films spontaneously detached from the regenerated skin areas. The exact mechanism 
underlying the improved clinical performance observed for the silk film group over the 
Sidaiyi group is currently unknown. 
 
However, this study demonstrated the ability to manufacture silk films under Good 
Manufacturing Practice requirements and their successful use as wound dressings for skin 
repair and regeneration.[112] The potential for relatively easy modification of silk films for 
additional functionality, such as the incorporation of pores or the introduction of 
bioactive molecules [113], makes silk films particularly attractive as wound dressings.  
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Thin silk films have also been used in prospective human clinical trials to repair acute 
and chornic tympanic membrane perforations.[114] These silk patches (Tympasil, 
Daewoong-Bio, Seoul, South Korea) were generated using reverse engineered Bombyx 
mori silk fibroin. The process leading to stabilization of these silk patches has not been 
established, but physical cross linking is most likely because the brittle patches were first 
wetted in PBS to plasticize them to facilitate their trimming to the required size and 
surgical placement.  
 
The first clinical trial involved 52 patients with acute traumatic tympanic membrane 
perforation who were treated with either a silk film or a paper-based membrane.[114b] A 
number of conservative treatment modalities had been explored to support the (often 
spontaneous) healing of an acutely perforated tympanic membrane, including the 
placement of a ÒpatchÓ on top of the damaged tympanic membrane. In this trial, the silk 
or paper patches were surgically placed and removed 7 days later, when the tympanic 
membrane appeared fully regenerated. The closure rate was similar for both the silk film 
and paper membrane (92.3 and 84.6%, respectively), but the silk patch significantly 
shortened the healing time from 16.7 days to 13.7 days.  
 
A similar improved healing with a silk patch was also previously reported in animal 
studies.[115] A follow-up study of 40 patients with chronic traumatic tympanic membrane 
perforation showed that patients treated with a silk patch (Tympasil) had lower otorrhea, 
minor complication rates, and high patient satisfaction when compared with conventional 
perichondrium myringoplasty.[114a] The silk and autologous patches were removed one 
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week after placement, and the postoperative hearing outcomes were not significantly 
different between the two treatment groups. However, the surgical time for the silk patch 
was very short (13.7 versus 29.5 minutes) and no sourcing of connective tissue was 
required for the graft.[114a] 
 
9. Preclinical use of silk Ð the future 
As we move from the routine clinical use of silk fibers to human clinical trials, the line 
between a silk thread-based medical device and other forms of silk starts to blur. A very 
wide spectrum of silk materials and formats is now emerging in pre-clinical studies. We 
will first review silk solutions derived from reverse engineered Bombyx mori silk, 
followed by more complex formulations.  
 
9.1 Silk solution 
 
Bombyx mori silk in its solubilized aqueous form has been investigated for a range of 
therapeutic applications, including treatment of diabetes [116], chronic wounds [117], and 
inflammation [118]. Recent studies have investigated the utility of regenerated silk fibroin 
solution in preclinical animal models for the treatment of ocular conditions, including dry 
eye [119] and corneal injuries.[5b] Blindness from corneal disease affects over 50 million 
people worldwide, while another 337 million people suffer from dry eye disease, 
representing a significant healthcare burden.[5b, 120] 
 
For example, silk fibroin treatment resulted in increased tear production and reduced the 
corneal irregularities observed in the absence of treatment in a mouse dry eye model 
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(consisting of NOD.B10.H2b mice exposed to desiccation stress and scopolamine 
hydrobromide treatment for 10 days). Silk fibroin treatment inhibited detachment of 
corneal epithelial cells, increased the number of conjunctival goblet cells, and inhibited 
the secretion of inflammatory factors in the lacrimal gland of the eye, resulting in 
recovery of the tear film and mucus layer of the eye, improved corneal health, and 
reduced dry eye symptoms. Other anti-inflammatory agents, such as cyclosporine and 
corticosteroids, are available on the market for the treatment of dry eye, but silk has 
demonstrated a potential multi-target therapeutic effect that lacks the common side 
effects, such as pain and irritation, and other complications associated with long-term 
corticosteroid use.[43] Silk fibroin was demonstrated to stabilize the tear film through anti-
inflammatory effects in the lacrimal gland and increased number of conjunctival goblet 
cells, but the mechanisms underpinning these obesrvations are unknown.  
 
Clinical approaches to treat corneal injuries are relatively limited and predominantly 
involve topical application of anti-inflammatory or anti-microbial agents that do not 
promote tissue regeneration. A rabbit corneal injury model, which involved removal of a 
7 mm diameter section of the central corneal epithelium, was used to study the effects of 
an aqueous Bombyx mori silk fibroin solution (deemed Òsilk-derived proteinÓ due to an 
additional autoclaving step during solubilization in lithium bromide that results in a 
heterogeneous population of low molecular weight silk fragments) on corneal epithelial 
healing.[5b] All treatments showed corneal wound closure by 48 hours post-injury, as 
indicated by fluorescein staining; however, treatment with silk accelerated the rate of 
wound healing 3-fold in the first 6 hours post-injury. Relative to a PBS-treated control, 
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silk treatment resulted in a significant increase in the numbers of proliferating Ki-67 
positive epithelial cells, a dose dependent increase in epithelial cell attachment to the 
underlying basement membrane (as indicated by focal adhesion kinase staining), and a 
dose-dependent reduction in MMP-9, a metalloprotease involved in matrix remodeling 
and corneal repair. Finally, compared to the PBS-treated control, the silk-treated group 
showed the formation of epithelial layers with tight junctions (ZO-1 staining) that more 
closely resembled those of healthy corneas.[5b]  The potential of the silk solution in aiding 
wound healing is clearly demonstrated, but the exact mechanism of action is yet to be 
determined.  
 
9.2 Silk films 
Silk films are among the most extensively explored biomaterials due to the ease of their 
fabrication and characterization and their versatility. Silk films have been explored for 
their potential in drug delivery [60b], wound healing [112-113, 121], corneal replacement, and 
flexible electrode [122] applications, among others.  
 
Due to their transparent nature, silk films have been particularly well explored for ocular 
applications, including corneal and retinal regeneration. Silk films cast from the Indian 
non-mulberry tasar silkworm Antheraea mylitta (which as mentioned previously, unlike 
Bombyx mori silk, contains a natural RGD sequence) displayed a transparency 
(94.4±0.006%) and a refractive index (1.44±0.03) suitable for corneal repair [123]. These 
films supported the sprouting, migration, attachment, and proliferation of epithelial cells 
and keratocytes from rat corneal explants to form complete cell sheets. Further, the films 
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supported the growth of corneal limbal stem cells from the explants. Silk films cast from 
Bombyx mori silk have also been shown to support the adhesion and growth of human 
corneal epithelial cells as confluent epithelial sheets similar to those on the amniotic 
membranes used clinically.[124] Further, silk film topography [125] and biofunctionalization 
[126] can be optimized to enhance corneal epithelial cell interactions.  
 
Following implantation into the corneal pockets of rabbits, acellular silk films made from 
Antheraea mylitta silk remained transparent and showed no signs of 
neovascularization.[123] The films remained intact for at least two months and had no 
adverse effect on tear production, intraocular pressure, electrophysiology of the eye, or 
the histology or ultrastructure of the cornea. Silk film degradation can be controlled 
through modification of its β-sheet content and this has been extensively used to optimize 
silk biomaterial properties, including those of silk films for corneal applications.[58, 127]  
 
Silk films are also extensively explored for engineering corneal stroma [12, 128] and the 
development of in vitro corneal models incorporating epithelium, stroma, and 
innervation.[6c] In addition to corneal repair and regeneration, silk films are also being 
investigated as a substrate for the development of retinal prostheses. Recently reported 
retinal prostheses consisting of semiconductive poly(3-hexylthiophene) (P3HT) and 
conductive poly(3,4-ethylene-dioxythiophene)-poly(styrenesulfonate) (PEDOT:PSS) 
layers spin-coated onto silk films were shown to restore light sensitivity and visual acuity 
of the primary visual cortex in a well-established rat model of retinitis pigmentosa.[129]  
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Another promising application of silk films involves the introduction of various 
topographical features, such as microneedles. Microneedles are a minimally invasive and 
painless alternative to hypodermic needles for drug administration. Silk microneedles 
have been made using micromolding approaches and a variety of masters, including those 
made by thermal drawing [130], micromilling followed by wet etching [131], and laser 
micromachining [39a]. DeMuth and colleagues proposed an interesting approach to 
develop implantable-tip composite microneedles using poly(acrylic acid) (PAA) and 
Bombyx mori silk fibroin for sustained vaccine delivery (Figure 5).[39a] Recent studies 
have shown the importance of antigen and adjuvant delivery kinetics in developing an 
optimal immune response, and persistent antigenic and inflammatory signals have been 
shown to elicit stronger responses when compared with transient bolus vaccine 
exposure.[96, 132]  
 
Silk has the advantage of controlled cargo release over time and can protect temperature-
sensitive cargoes at elevated temperatures, potentially allowing elimination of the Òcold 
chainÓ that limits the availability of vaccines in developing countries.[133] The composite 
microneedle consists of a silk fibroin tip loaded with the vaccine of interest and vaccine-
loaded PAA microneedle pedestals.[39a] Upon exposure to the aqueous environment of the 
skin, the PAA rapidly dissolves within hours, releasing a bolus vaccine injection, while 
the silk fibroin tips remain implanted in the skin, releasing the vaccine over days. The 
microneedles were demonstrated to easily penetrate murine skin, with insertion occurring 
several hundred microns below the skin surface. The skin healed within a day of patch 
application. A fluorescently labeled model protein was used to demonstrate vaccine 
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release, and rapid PAA-delivered cargo clearance was observed from the treatment site 
within 24 hours, followed by a slow release of silk-encapsulated cargo at the treatment 
site between 4 days (when silk fibroin was not treated with methanol) and >16 days 
(when silk fibroin was treated with methanol), indicating the ability to tune the drug 
release. When used to deliver a model whole-protein vaccine, the composite platform 
resulted in over a 10-fold increase in antigen-specific T-cell and humoral immune 
responses when compared to traditional immunization approaches. Notably, the 
microneedles were stored at room temperature for two months prior to testing, 
demonstrating the potential of this technology to eliminate the cold chain.  
 
9.3 Silk scaffolds 
Three-dimensional porous silk scaffolds can be manufactured via a number of approaches 
[41], including the use of sodium chloride as a porogen leached from aqueous or organic 
silk solutions or following freezing and lyophilization of aqueous silk solutions.[39c] Early 
applications of these biomaterials predominantly focused on bone replacement and 
regeneration [134] due to the high mechanical strength of silk scaffolds and the potential 
for further reinforcement using degummed silk fibers, which approached the mechanical 
properties required for load-bearing bones.[63] Silk scaffolds have since found 
applications in a range of tissue engineering procedures for replacement and regeneration 
of tissues [113, 135], as well as in the development of 3D in vitro tissue models.[6c, 39c]  
 
Recently, silk-based (Bombyx mori) fracture fixation devices have been developed using 
an approach that differs from the use of traditional highly porous silk scaffolds. Metal 
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alloys are the current gold standard for fracture-fixation devices, despite issues arising 
from the extreme mechanical mismatch with native bone, which can have profound 
effects on wound healing and long term viability of the devices, particularly in pediatric 
patients.[136] Resorbable fixation devices, such as those made of PLGA, PGA, and, 
recently, silk, have the potential to address the disadvantages of metallic fixation devices.  
Silk, in particular, has the advantage of maintaining high strength while eliciting a low 
inflammatory response. Furthermore, silk degradation does not generate an acidic 
microclimate, as is typically observed for solid PLGA and PGA devices.[137] Bombyx 
mori silk fibroin fixation devices, including bone plates and bone screws, were 
manufactured from lyophilized regenerated silk fibroin by casting in 
hexafluoroisopropanol, followed by machining into desired shapes (Figure 6).[138] Silk 
screws were successfully inserted into the hind limbs of rats (a non-functional pre-clinical 
model) to demonstrate the feasibility of the manufacturing and insertion process. The rats 
were mobile immediately following surgery and showed no visible signs of pain. The 
screws were well tolerated for up to 8 weeks, with early signs of resorption and formation 
of new bone evident around the threads of the screw. These devices are particularly 
appealing due to the potential for malleability when hydrated, which will allow shaping 
of the fixation plates for unique anatomical locations during surgery, as well as providing 
the potential to incorporate BMP-2 or antibiotics directly into the fixation devices to 
increase their functionality.  
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9.4 Electrospun silk biomaterials 
Electrospinning has emerged as a popular technique for the development of biomaterials 
due to the ECM-like fibrous nature of the non-woven matrices and the control over fiber 
properties that can be achieved by tuning the electrospinning parameters. Electrospun silk 
fibroin has been explored for a range of applications, including wound dressings [113, 139], 
bone [140] and ligament [141] replacements, and vascular grafts.[142] Small diameter 
electrospun silk conduits have the potential to address the unmet need for off-the-shelf 
small diameter grafts with mechanical properties that match those of native vessels and 
support appropriate endothelial and blood cell interactions. In a comprehensive in vivo 
study of small diameter electrospun silk graft performance, Filipe and colleagues have 
demonstrated the production and performance of electrospun acellular silk fibroin grafts 
generated under aqueous conditions in the absence of chemical cross-linkers (Figure 
7).[142c] The electrospun silk fibroin grafts were significantly more elastic when compared 
with the gold-standard synthetic polytetrafluoroethylene (ePTFE) grafts (4.2±0.5 MPa vs 
31.9±1.3 MPa) and more closely matched the elasticity of native rat vessels (2.1±1.0 
MPa), while demonstrating adequate burst pressure (849 mmHg) and suture pull-out 
strength (0.86 N). In vitro, the electrospun silk fibroin demonstrated excellent endothelial 
cell interactions and blood compatibility.  
 
These characteristics are critical for the successful development of next-generation 
vascular grafts, because only grafts that have both outstanding hemocompatibility and 
support endothelialization will yield long-term performance. In an in vivo rat model of 
abdominal aortic replacement, electrospun silk fibroin scaffolds demonstrated excellent 
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surgical handling and patency for up to six months and outperformed the gold-standard 
ePTFE grafts. Silk fibroin grafts supported rapid endothelialization, with endothelial cells 
present as early as 3 weeks post-implantation and an almost complete monolayer forming 
by 6 weeks (Figure 7). By contrast, the ePTFE grafts remained largely uncovered by 
endothelial cells even at 24 weeks post-implantation. The silk fibroin grafts showed 
intimal hyperplasia stabilization by 6 weeks, with smooth muscle cells (SMCs) showing a 
phenotypic switch to the less proliferative SMC-α expressing cells and increases in 
collagen, elastin, and proteoglycan production.[142c] This study demonstrates the potential 
for the use of silk fibroin in small diameter vascular graft applications and the findings 
warrant further pre-clinical testing in large animal models.  
 
 
 
9.5 Hydrogels  
Silk fibroin hydrogels have emerged as promising platforms for the delivery of small 
molecular weight drugs, biologics, and cells (reviewed in [143]), as well as for mimicking 
of the ECM in three-dimensional in vitro tissue models (reviewed in [144]) and in vivo 
tissue fillers.[145] A classification of physically and chemically cross-linked Bombyx mori 
silk hydrogel is useful. The chemically cross-linked forms will not be discussed here 
(reviewed in [143b]), because these systems do not capitalize on the facile self-assembly 
process of silk fibroin, a feature that sets it apart from many other (bio)polymer-based 
hydrogels. This ability to self-assemble arises because silk I can undergo a transition to 
silk II, which is rich in β-sheets, by the exclusion of solvating water molecules from the 
hydrophobic domains of the silk block copolymer. The GY sequences are key drivers for 
the formation of β-sheets, while the exact molecular abundance and composition allows 
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fine tuning of the solution-gel transition process. Furthermore, pH responsive elements 
within the silk structure allow silk to adopt a more ordered state (reviewed in [146]).  
 
Many different triggers have been used to control the solution-gel transition, including 
but not limited to (i) vortexing, (ii) ultrasound, (iii) temperature, (iv) osmotic stress, (v) 
pH, (vi) CO2 acidification, (vii) non-solvent induced phase separation, and (viii) direct 
electric current (reviewed in [147]). Self-assembling silk fibroin hydrogels show shear 
thinning, making them ideal for injection and minimally invasive procedures. Treatment 
protocols are now available that yield self-assembling hydrogels in the absence of organic 
solvents, chemically cross linkers, or UV irradiation. However, a potential disadvantage 
of self-assembling silk fibroin hydrogels is that physically crosslinked systems (i.e., those 
with high β-sheet content) are opaque, due to the formation of nanocrystallites, and they 
are brittle, as they cannot undergo long range displacements, resulting in low elastic 
behavior and plastic deformation at strains >10%. 
 
Electric fields yield silk fibroin hydrogels (also known as e-gels) that differ from most 
other physically cross-linked types.[148] First, the secondary silk structure of e-gels is 
dominated by helical conformations, whereas other (pH-induced) hydrogels are rich in β-
sheets. Second, e-gel formation is reversible: a switch in the DC current induces a 
migration of silk to the new positive electrode (this is possible because of the absence of 
strong β-sheets). Third, e-gels have strong adhesive properties that are typically absent 
from other silk fibroin hydrogels. Fourth, e-gels have outstanding elastic properties and 
can withstand strains up to 2,500%.[148]  
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The assembly of silk micelles into an e-gel at the electrode is completed within minutes. 
The local drop in pH at the positive electrode below the isoelectric point of silk screens 
repulsive charges and enables hydrogel formation.[149] Overall, e-gels have been proposed 
to support a range of biomedical applications (e.g., adhesives for medical devices, 
sensors, etc.) and proof of principle studies are eagerly awaited. 
 
Self-assembling Bombyx mori silk fibroin hydrogels with a high β-sheet content have 
also been explored for a broad range of biomedical applications. For example, self-
assembling silk fibroin hydrogels were loaded with doxorubicin and administered locally 
to breast tumors in mice. Locally administered silk fibroin hydrogels loaded with 
doxorubicin provided a significant reduction in primary tumor growth and metastasis 
when compared to equivalent doses of doxorubicin administered systemically.[150] A 
parallel study that used the same animal model, drug, dosing schedule, and treatment 
strategy showed that the heparin-modified PEG hydrogels were outperformed by the self-
assembling silk hydrogel.[151] Self-assembling silk fibroin hydrogels that use sonication 
as a trigger are ideal for the delivery of biologics. The payload is added following 
sonication and during the solution-gel transition time window. For example, self-
assembling silk fibroin hydrogels have been examined for the delivery of bevacizumab (a 
monoclonal antibody of antivascular endothelial growth factor) for the treatment of age-
related macular degeneration.[152]  
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Direct comparison of a silk fibroin hydrogel formulation with the current standard 
treatment showed that intravitreal injection in healthy rabbits significantly improved the 
drug levels in the vitreous and aqueous humor when compared to the commercial liquid 
formulation. The bioavailability of the commercial product and the silk fibroin hydrogel 
formulation were similar, but the terminal half-life for the silk hydrogel was 2 to 3 fold 
higher. This improvement would be expected to reduce the number of intravitreal 
injections required.[152] Although the results are encouraging, further optimization of the 
silk fibroin hydrogel is warranted to reduce the initial burst release of bevacizumab and 
the placement of the silk hydrogel, because vitreous administration has the potential to 
obstruct the light path into the eye and thereby limit vision.  
 
Self-assembling silk hydrogels are emerging as useful tools for the therapeutic delivery of 
(stem) cells. For example, pancreatic islet transplantation is plagued by a functional 
decline and decreased viability of the islets during the peritransplantation period, so self-
assembling silk fibroin hydrogels have been examined as a potential delivery system.[153] 
Silk self-assembly was initiated by vortexing, the islet cells were added prior to the 
completion of the solution-gel transition, and the mixture was injected into the 
epididymal fat pad of diabetic mice. Functional tests showed that silk fibroin hydrogels 
loaded with pancreatic islets were able to control glucose levels within 4 days, whereas 
this time was extended to 14 days in the absence of the silk carrier matrix. Intraperitoneal 
glucose tolerance tests showed that co-transplantation of mesenchymal stem cells (MSCs) 
with the islets improved the function of the graft through the production of trophic and 
angiogenic factors. Furthermore, transplantation of minimal islet cell grafts and MSCs 
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(serving as a supporting stromal cells) using self-assembling silk fibroin hydrogels 
resulted in euglycemia control in 75% of the transplanted mice at day 37, whereas no 
other treatment combinations successfully abolished diabetes.[153] The use of a silk fibroin 
hydrogel maximized the clinical performance; however, histological examination showed 
an unintended complication as the MSCs differentiated into osteoblasts at day 42. MSCs 
are responsive to environmental cues (e.g., mechanical forces, cytokines, etc.), which 
indicates that (silk) hydrogels still require fine-tuning to ensure the final desired outcome.  
 
 
9.6 Particles 
The pre-clinical development of silk (nano)particles is often aimed at the delivery of 
cytotoxic small-molecular-weight anticancer drugs (reviewed by [69]). Entrapment into a 
(nano)particle changes the pharmacokinetic and biodistribution characteristics of the 
payload, as these characteristics are now dictated by the carrier and not the 
physiochemical properties of the drug. Therefore, engineering the carriers opens up new 
possibilities for tuning the overall drug performance; for example, by altering the 
residence time in the blood or the uptake mechanism into target cells. Nanoparticles are 
often proposed for solid tumor targeting as they can exploit the leaky vasculature and 
reduced lymphatic drainage associated with tumors, which results in enhanced 
permeability and retention (EPR) at the target tissue.[154] Inclusion of a targeting ligand 
can further increase the specificity. The EPR effect exploits pathophysiology, but full 
clinical exploitation remains to be realized.[155] Nanoparticles designed for EPR-mediated 
tumor targeting are typically injected into the blood circulation and must therefore be 
compatible with blood. Silk fibroin nanoparticles showed very low plasmatic coagulation 
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and the observed response was significantly better when compared to silica nanoparticles. 
Furthermore, under simulated venous blood flow, the silk and PEGylated silk fibroin 
nanoparticles also showed low inflammation when compared to silica nanoparticles.[71] 
Overall, these initial studies on the hemocompatibility of silk fibroin nanoparticles are 
encouraging. 
 
Early studies set out to explore techniques for the manufacture of silk fibroin 
nanoparticles and to establish their respective loading capabilities using (model) drugs 
(reviewed by [156]). Two of the early manufacturing techniques used to generate silk 
fibroin nanoparticles were nanoprecipitation [157] and capillary micro-dot printing.[158] 
Capillary-dot microprinted nanoparticles loaded with curcumin showed extended release 
profiles and a higher in vitro efficiency against breast cancer cells when compared to 
silk/chitosan composite nanoparticles.[158] Nanoparticles generated from Bombyx mori 
and Antheraea mylitta (the tropical tasar silkworm) silks were stable, spherical, 
negatively charged, and 150 to 170 nm in diameter, and they showed no cytotoxicity at 
the tested concentrations.[159]  
 
The delivery of small molecular weight drugs with (silk) nanoparticles changes their 
uptake mechanisms (and their susceptibility to drug efflux pumps) from passive diffusion 
across the plasma membrane to an energy-dependent endocytic uptake (independent of 
drug efflux pumps). For these reasons, silk fibroin nanoparticles were able to improve 
anticancer drug delivery into drug resistance breast cancer cells.[160]  
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Once inside the cells, the payloads on silk fibroin nanoparticles can also be activated 
within lysosomes (i.e., lysosomotropic drug delivery) by the low pH and the proteolytic 
enzymes of lysosomes, given the correct intracellular trafficking of the nanoparticles.[161] 
The lysosomal environment not only triggers drug release but is also the site of silk 
fibroin nanoparticle degradation.[50] Silk fibroin (nanoparticles) can stabilize a broad 
spectrum of payloads by tailoring the water content, locking the payload into place, 
buffering the microenvironment, and restricting the access of degradative enzymes 
(reviewed in [133]). For example, entrapment of L-asparaginase into Bombyx mori silk 
fibroin nanoparticles resulted in an increased resistance to enzymatic degradation, better 
stability in serum, prolonged storage stability in solution, and minimal leakage of the 
enzyme from the carrier.[162] PEGylation of silk fibroin nanoparticles has been exploited 
to improve colloidal stability and to tailor drug release and carrier degradation.[163] 
Magnetically responsive, drug-loaded silk fibroin nanoparticles have also been developed 
by seeding silk with Fe3O4 nanoparticles.
[164] Subjecting these silk nanoparticles to a 
magnetic field in the tumor area allowed their enrichment in the tumor, thereby 
promoting drug accumulation and an improved antitumor response [164]. Silk fibroin 
nanoparticles have also been combined with other silk formats (for example, silk fibroin 
hydrogels) to yield first generation all-silk dual-drug delivery systems.[165]  
 
10. Bioengineered silks 
Recent efforts have focused on developing recombinant forms of silks that can be altered 
at the sequence level to achieve specific modalities, for example, for biomedical use.[166] 
Recombinant approaches are unique because they allow the design and manufacture of 
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bespoke ÒsilksÓ.[167] For example, key elements of the spider silk sequence can be lifted 
and combined with polylysine to develop novel biopolymers for the delivery of genetic 
material (reviewed in [168]). Chimeric proteins, such as silk-collagen-like proteins[169] or 
silk-elastin-like proteins (SELPs), are exciting new materials (although the SELPs have 
been extensively studied over the past 3 decades; reviewed in[170]). SELPs are facile 
biopolymers that can be fine-tuned to achieve a desired form and function; for example, 
SELP micelles have been designed for anticancer drug delivery that exploits both passive 
and active tumor targeting. SELPs have also been used to generate hydrogels intended for 
local drug release.[170] Many other studies have examined the performance of 
Òbiopolymer alloysÓ by blending silk with another biopolymer, such as tropoelastin[171], 
collagen[172], and fibronectin[173] or have included inorganic ceramics (reviewed in [174]) to 
generate new material systems with expanded function. One of the hallmarks of silk is its 
inherent ability to organize structures at the nanometer scale; these structures then 
assemble, grow, and ultimately produce macroscale constructs with defined function. The 
ability of silk to work seamlessly across several orders of magnitude is exciting and has 
motivated the development of engineered nanoscale systems. For example, atomic force 
microscopy has been used to drive and direct the self-assembly of SELP nanofibers[175], 
while macroscopic silk constructs have been patterned using ion beam lithography to 
yield diverse silk-like constructs with defined shapes at the nanometer scale.[176] Other 
examples include engineered silk oligonucleotide conjugates that direct silk assembly 
into a parallel, antiparallel, and branched configurations (reviewed in[177]).The timely 
review by Aigner et al. provides extensive insight into this important branch of silk 
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research.[166] Here, we only provide a selection of a few examples of recombinant silks 
(Table 4), with a specific reference to silk (nano)particles.  
 
 
Recombinant silk proteins have been inspired by Araneus diadematus fibroin 4 (ADF4); 
ADF4 is from the common European garden spider. ADF4 is one of the most widely 
studied spidroins [5a] and has been used to prepare microcapsules for drug delivery by 
exploiting its self-assembly at an emulsion interface.[186] The resulting spider silk-based 
carriers are useful for encapsulating low molecular weight drugs under mild conditions, 
which maintains the activity of the payload.[186] Exposure of ADF4-like silks to 
potassium chloride (>400 µM) generates particles [187], which have been extensively 
characterized for their ability to entrap and release (small molecular weight) payloads.[188] 
Silk sequence modifications are now yielding cationic proteins that can be loaded with 
low and high molecular anionic payloads (e.g., nucleic acids).[189] Libraries of silk 
proteins containing modifications, such as the RGD integrin binding domain and the Tat 
cell penetrating peptide, have been designed to enhance cellular uptake and drug 
delivery.[190] The first inroads have been made to unravel the mechanisms for endocytic 
(e.g., caveolae, clathrin-mediated) uptake of nanoparticles into cells using putative 
chemical inhibitors.[191]  
 
Recombinant technologies have also been exploited to generate silks inspired by major 
ampullate spidroin 1 (MaSp1) from the Gold Orb-web spider (Nephila clavipes). For 
example, MaSp1-like proteins have been modified with poly(L-lysine) cationic sequences 
to allow complexation with nucleic acids via electrostatic interactions for use in gene 
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delivery. These engineered protein vectors demonstrated excellent DNase resistance and 
gave transfection efficiencies similar to those achieved with the commercial reagent 
Lipofectamine 2000. The silk sequence has also been fused with tumor-homing peptides 
(e.g., F3, Lyp1 CGKRK) and attachment ligands (e.g., RGD to exploit cell binding and 
receptor-mediated endocytosis) to enhance their targeting capabilities.[60c, 92, 165] These 
recombinant silks formed nanometer-sized globular complexes with plasmid DNA (150 
to 250 nm in diameter), and they demonstrated significantly improved target specificity 
for melanoma and highly metastatic human breast cancer cells.[92, 165] A silk vector 
harboring the tumor-homing peptide F3 showed minimal toxicity in healthy cells, the best 
tumor specificity, and a capability to deliver its payload in a human orthotopic breast 
cancer model.[192] Overall, these studies demonstrate the potential of silk-based delivery 
systems as non-viral gene delivery vectors. 
 
11. (Old) New silk industries: opportunities and challenges for the road ahead 
Current production routes for Bombyx mori silk are well established and are the 
foundation of several products in routine clinical use today. Following a period of 
decline, global silk production is growing once again and has the capacity to keep up with 
a growing silk demand for (bio)medical use.[18] However, sericulture is an agricultural 
process that depends on several factors, including, but not limited to, climate, seasonal 
variations, disease and pest control, and the susceptibility of silkworms to common 
pesticides used in other agriculture sectors (within geographical proximity, with fatal 
consequences for the silkworm). The silk community should make a concentrated effort 
to work with well-controlled silk cocoon stocks with a known process history in order to 
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propel the silk research community into working practices that align with Good 
Laboratory Practice. This type of approach would be invaluable for improving 
comparisons across different studies and accelerating clinical translation. While public 
guidelines exist for CE-marked organic sericulture, the production of Bombyx mori silk 
for medical use is shrouded in secrecy and proprietary protocols. For example, the 
domesticated Bombyx mori silkworm line used for silk sutures and surgical meshes is a 
well-kept secret.  
 
The optimal environmental condition during cocoon spinning is another unknown. 
Laboratory experiments indicate that silk cocoons spun in a low humidity environment do 
not require degumming by boiling in an aqueous alkaline solution; instead, physical 
manipulation is sufficient for quantitative removal of sericin.[193] Of course, adequate silk 
cleaning is critical for producing hypoallergenic silk. Eliminating the boiling step also 
preserves the silk structure, thereby yielding a mono-dispersed biopolymer (rather than 
polydispersed silk fibroin fragments). This, in turn, is likely to simplify the regulatory 
requirements that currently mandate a well-defined material stock (although these 
regulations vary depending on the specific classification of the final product as Òmedical 
deviceÓ, ÒexcipientÓ, Òadvanced therapy medicinal productÓ, Ònovel chemical entityÓ 
etc.).     
 
Full reverse engineering of the silk cocoon is complex from both industrial and 
regulatory perspectives. At present, all licensed (Bombyx mori) silk products in the USA 
and EU are considered medical devices based on the nascent, but degummed, silk fiber 
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(Table 1, 2 and 5). In contrast reverse engineered silk is marketed as cosmetics to 
navigate regulatory challenges. Irrespective of the medical or cosmetic use, the current 
silk production technologies are batch processes, which go against the current industrial 
efforts aimed at continuous manufacturing to ultimately improve product reliability and 
cut costs.  
 
Manipulating (the germ line of) silkworms by genetic engineering opens up new 
possibilities to generate improved silks, for example, by inserting spider silk sequences 
into Bombyx mori silk to improve the mechanical properties of the in vivo spun fiber.[194] 
Another possibility is to exploit the silkworm as a biosynthetic host to synthesize 
xenogenic proteins or functional silks (e.g., insertion of green fluorescent protein, RGD 
sequences, etc. [195]). Improvements in genome editing are likely to increase the protein 
yields, ultimately leading to new silkworm lines (e.g., that produce modified silk 
sequences etc.) of appreciable economic value. 
 
Recombinant proteins are routinely used in the clinic and are manufactured on a large 
scale by the pharmaceutical industry. Therefore, the necessary expertise exists within the 
healthcare sector to manufacture these complex products to clinical specifications. 
Already, today, recombinant DNA technology, in combination with Escherichia coli 
expression systems, has revolutionized silk research [166] and is opening up new 
commercial avenues (Table 5). However, silk presents a number of specific challenges; 
for example, the silk molecules cannot be post-translationally modified, but this is 
required to faithfully mimic the silk protein.[196] The expression of native-sized silk 
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proteins is also not possible using standard E. coli expression systems because of the 
highly repetitive nature of the gene constructs, the very high glycine content of the 
protein, and the high molecular weight of the product (250Ð320 kDa). These challenges 
can be addressed by using genetically modified E. coli with an elevated glycyl-tRNA 
pool, which give native-like silk proteins, albeit with a low protein yield.[197] Another 
complication is that silk inspired proteins with repeated domains containing Ala-rich 
sequences are poorly soluble in water and buffers. Inclusion of a cationic histidine tag 
with the hydrophobic crystallizable silk sequences improves the aqueous solubility of the 
resulting protein.[60c] The economic issues and greenhouse gas emissions associated with 
E. coli cultures are other critical aspects that must be considered for the development of a 
sustainable recombinant silk industry.[198] 
 
11.1 Staying on the Òsilk roadÓ  
Perhaps one of the most important aspects to consider regarding the future of the 
biomedical use of silk is the safeguarding of the silk development pipeline. Silk is a truly 
amazing biopolymer that has inspired generations of scientists and is likely to continue to 
do so. However, researchers must not get carried away or over promise. In a globally 
connected world, with many clinically unmet needs, the news of promising biomedical 
research has the potential to make headlines simply by the fact that the material is ÒsilkÓ. 
We must not exploit the familiarity of the general population with common silk for the 
purpose of short term gains. The road to the clinical translation of basic biomedical 
research is a long and tortuous one Ð this also applies to silk research. The path is difficult 
and requires a carefully measured balance of optimism (to inspire people) and realism (to 
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avoid a silk bubble). It is important to learn from past failures as well as from the 
challenges experienced in allied fields.[199] Clearly, silk has its limitations, as detailed in 
this review; for example, (i) it is an expensive biopolymer when compared to mass-
produced fully synthetic polymers, (ii) sericulture is a labor-intensive agricultural process 
and highly responsive to its environment, which ultimately impacts silk quality, and (iii) 
the durability of recombinant spider silks might be challenging based on the simple 
premise that the material has evolved in nature as a short-term high-performance material 
(e.g., orb-weaver spiders repair or build a new web often daily). It is therefore important 
to consider alternative materials as well that are able to perform, and perhaps surpass, the 
function of silk. The emergence of fully synthetic sutures is a testament to this type of 
development. However, silk fibroin sutures still remain the first choice for specialized 
surgeries, indicating that silk should serve as a blueprint for next generation sutures.  
 
11.2 The current silk drivers  
Silk continues to inspire and serves as the thread for exploration new avenues: curiosity-
driven research and learning from nature are key elements for innovation. Newly 
emerging silk industries are now translating research findings that go beyond fiber 
technology[200] (Table 5). As these technologies, which often have their origins in the 
academic setting, move from the public domain into the industrial space, tracking their 
progress becomes more difficult. However, the first products have entered clinical trials 
and products are emerging on the market (Table 5 and detailed below).    
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Recombinant (spider) silks are the lifelines of many small to medium sized enterprises. 
Spider silk is a prime focus, because this remarkable biopolymer cannot be obtained at an 
industrial scale by Òfarming.Ó Instead, genetic engineering and recombinant expression 
systems are essential, and they also provide greater flexibility and rapid production of 
novel silk-inspired proteins. The (pharmaceutical) industry is accustomed to working 
with recombinant proteins, and these provide many opportunities for patterning and 
proprietary knowledge. Many companies currently working with recombinant silks are 
generating fibers. The remarkable mechanical properties of spider silk, coupled with its 
processing under ambient conditions in an all aqueous environment, might serve as an 
inspiration for this new industry.   
 
The Synthetic Bioproducts Center, under the leadership of Randy Lewis (Utah State 
University, Logan, UT, USA), produces synthetic spider silks for biomedical engineering 
applications using a range of expression hosts, including genetically modified goats. 
These genetically engineered dairy goats carry the dragline silk genes of the Nephila 
clavipes (identified by the Lewis lab [201]) in mammary gland cells and excrete soluble 
silk in their milk. This silk can be extracted and subsequently spun into fibers. The 
genetically modified goats were developed by Nexia Biotechnologies Inc. (Quebec, 
Canada) in the early 2000s and subsequently acquired by Randy Lewis. Nexia 
Biotechnologies and the Materials Science Team of the U.S. Army Soldier Biological 
Chemical Command (Natick, MA, USA) expressed the silk proteins ADF-3/MaSp2 and 
MaSp1 for the first time in mammalian cells [202], thereby laying the foundation for 
subsequent work in goats. 
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AMSilk GmbH (Planegg/Munich, Germany) is a spinoff company based on seminal work 
by Thomas Scheibel and co-workers and is the worldÕs first industrial supplier of 
recombinant silk biopolymers across a range of applications. AMSilk exploits ADF4-
inspired silks to generate high quality materials for apparel, cosmetic, industrial, and 
structural applications. Biosteel¨ fiber is their leading product, and it is at various 
developmental stages for application in the footwear and automotive industries. AMSilk 
received ISO 13485 accreditation in 2017Ña prerequisite for initiating clinical studies in 
humans. In February 2018, AMSilk announced the launch of the POSIS Phase I clinical 
trial, in partnership with POLYTECH Health & Aesthetics GmbH. The trial examines the 
performance of silicone breast implants coated with ADF4-based silk (BioShield-S1) 
(SILKline¨) in several human subjects at a number of University hospitals in Austria 
(with the option to expand to other centers). This trial has been underpinned by both 
proprietary product development efforts, as well as animal studies available in the public 
domain. For example, ADF4 coated silicone implants showed no acute toxicity or 
immunogenicity and they reduced post-operative inflammation and minimized implant-
induced capsule thickness and contraction when compared to uncoated control 
implants.[203] 
 
Founded in 2008, Spiber Technologies AB (Stockholm, Sweden) produces Spiber¨ silk 
biomaterials, which can be processed into a range of material formats (e.g., fibers, films, 
foams, coatings, etc.). Their work is underpinned by academia-industry collaborations 
that support the pre-clinical Research and Development pipeline exploiting spider silk for 
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biomedical applications (e.g., cell-matrix interactions, culture matrices, surface 
modifications, and electrochemical meshes etc.).[204] Scientists affiliated with Spiber 
Technologies AB have also unraveled the molecular mechanisms of spider silk spinning 
[205] in order to develop better biomimetic fibers.[206]  
 
The pH-sensitive N-terminal of silk enables the silk protein to stay in solution at very 
high protein concentrations; thus, recombinant fusion of the N-terminal domain 
converted an aggregation-prone therapeutic protein to its hyper-soluble counterpart (this 
technology is now marketed as SolvNT¨).[207] This strategy also simplified protein 
purification, improved yields, and allowed the expression of non-transmembrane proteins 
that are otherwise refractory to recombinant production. SolvNT¨ exemplifies how silk 
continues to amaze us, and goes beyond applications we are accustomed to. 
 
Spiber Inc. (Yamagata, Japan), founded by Kazuhide Sekiyama in 2007 as a start-up at 
Keio University, produces various types of recombinant proteins, especially spider silk-
like proteins. (Note that Spiber Inc. is an independent company from Spiber Technologies 
AB). The synthetic spider thread QMONOSª (based on the Japanese word kumonosu 
for spider web) is a technology fiber that has been fed into several proof of concept items, 
such as a childÕs dress, and The North Face branded MOON PARKA¨. The current 
target markets are the apparel and automotive segments, with healthcare materials serving 
as an emerging future area. 
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Another contender in the recombinant silk market space is Bolt Threads Inc. (Emeryville, 
CA, USA), which produces silk fibers by wet spinning (Engineered Silkª) using 
advanced yeast expression systems. The recombinant silk is produced on a scale that 
makes it a viable contender for broad applications. To date, Bolt Threads has already 
introduced several engineered Silkª fiber and Bolt Microsilkª products (e.g., ties, 
clothing etc). Whether these materials will also enter the healthcare arena is not known at 
present. 
 
12. Conclusions 
In this review, we have unraveled some of the mysteries of silk and critically examined 
the current and emerging clinical uses of silk. We eagerly await further clinical reports, 
especially on engineered second-generation silk materials, such as ÒsilkÓ-coated implants. 
For the past 5,000 years, silk has captivated humans, and it continues to amaze us as we 
explore new applications. The silk biopolymer represents a pioneer material for medical 
applications today, and yet, even after many centuries, it continues to be a valued suture 
material. As we continue to extract secrets from silk, we will be able to develop new Òold 
materialsÓ to address current and future biomedical needs.  
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Figure 1. Timeline: Milestones in the emergence of silk for biomedical applications. 
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Figure 2. Silk structure. (A) Solution conformation of Bomyx mori silk. Hydrophobicity 
pattern of the heavy chain with possible chain folding and micelle assembly of silk 
fibroin in water. (B) Two dimensional silk fibroin schematic. (C) Primary structure of the 
Bombyx mori  silk heavy chain. R01 to R12 and A01 to A11 represent the arrangement of 
12 repetitive and 11 amorphous regions, respectively. The approximate amino acid 
sequence of the R10 is shown by combination of sequences of i, ii and iii. (D) Hierarchal 
structure of spider silk. (E) Primary structure of spider silks. (Panel A adapted with 
permission from.[49] Copyright 2003 Macmillan Publishers. Panel B adapted with 
permission from [50] and panel C adapted with permission from [51], Copyright 2018 and 
2005 American Chemical Society. Panel D adapted with permission from [52] and panel E 
adapted from [53], Copyright 2011 Elsevier and Copyright 2017 American Association for 
the Advancement of Science). 
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Figure 3. Examples of SERI Surgical Scaffold¨ implant loss in humans. (A) Silk 
fibroin surgical mesh prior to implantation. (B) Intraoperative view showing a free lying 
scaffold in the breast pocket. (C) Retrieved scaffold surrounded with seroma. (D) 
Interaoperative view of surgically removed scaffold with interpenetrated granulation 
tissue/scar plate (at >5 months), and (E) histology of retrieved sample showing 
granulation tissue with neutrophiles and giant cells at the material (1) interface (dotted 
line). Images reproduced with permission (panel B, C) from [66b] and (panel D and E) 
from [105]. Copyright 2018 and 2015, Elsevier. 
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Figure 4. Silk fibroin films for wound healing applications. (A) Healing of rabbit full-
thickness wounds over a 21-day period following application of Bombyx mori silk fibroin 
films, a polyurethane based wound dressing Suprathel, a silk-silicone wound dressing 
Sidaiyi, and a blank control treated with PBS. Silk-filmÐtreated wounds healed 3 days 
faster than Suprathel-treated wounds and 7 days faster than Sidaiyi-treated and untreated 
wounds. (B) Histological evaluation of the wounds: (A) moderate to complete epidermal 
organization in silk film treated wounds by day 14 and mature regenerated tissue with 
well-formed collagen matrix by day 21. (C) Photographs of representative silk-filmÐ
treated partial thickness wounds in a human Phase I clinical trial, showing complete 
healing at day 11, with an average time for complete wound healing of 9.86 ±1.97 days 
(n=36). (D) KaplanÐMeier curves comparing cumulative healing by treatment group. 
Images reproduce with permission from [112]. Copyright 2017 Wiley. 
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Figure 5. Implantable poly(acrylic acid)-silk fibroin microneedles for controllable 
vaccine release kinetics and enhanced immunogenicity. (A) Schematic representation 
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of the composite microneedle fabrication process, showing fabrication of the silk fibroin 
tips followed by poly(acrylic acid) (PAA) pedestals. (B) Photograph of the composite 
microneedles, (C) Confocal microscopy images of composite microneedles loaded with 
fluorescently labeled model proteins in the silk tip (blue) or PAA pedestals (red) and (D) 
Delivery of fluorescently labeled model proteins to murine skin showing burst release 
and fast clearing from the PAA pedestal and slow, sustained release from the silk tip over 
4 days (non-methanol-treated silk) or 16 days (methanol-treated silk). i.d. inj refers to the 
intradermal injection control. Adapted from [39a]. Copyright 2014 Wiley. 
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Figure 6. Silk-based devices for fracture fixation. (A) SEM image of a silk fibroin 
screw. Scale bar is 1 mm. (B) Silk fibroin screw inserted into a rat femur at 4 weeks post-
surgery. (C-D) Cross-sections of the silk fibroin screw inserted into a rat femur at 4 
weeks post-surgery; sections stained with H&E and MassonÕs trichrome, respectively. 
Adapted from [138]. Copyright 2014 Macmillan Publishers. 
 
  
90 
 
 
 
Figure 7. Electrospun silk fibroin biomaterials for vascular applications. (A) 
Electrospun silk fibroin graft morphology. Scale bar is 10 µm. (B) Electrospun silk 
fibroin grafts implanted in a rat model of abdominal aortic replacement: at the time of 
implantation (left), 6 weeks (middle), and 24 weeks (right) post-implantation. (C) 
Endothelialization of implanted silk fibroin grafts as demonstrated by vWF+ staining 
(red) at 6 weeks post-implantation in distal (left), middle (middle), and proximal (right) 
regions. (D-E) In vitro assessment of blood compatibility of electrospun silk fibroin 
biomaterials, compared to ePTFE, as indicated by formation of a fluorescent fibrinogen 
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network (D) and whole blood incubation (E). Adapted from [142c]. Copyright 2018 
Elsevier. 
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Table 1. Published data reporting the clinical use of SERI Surgical Scaffold¨ in humans  
 
Year Article type Patient 
number 
 Study 
sponsor 
Intervention Clinical 
follow up 
(months) 
Reported outcome Reference 
2013 Retrospective case 
report 
1 Allergan Abdominoplasty and use 
of scaffold to provide 
soft-tissue support to the 
abdominal fascia in 
patient with massive 
weight loss  
24 Contour and flatness of the anterior 
abdominal wall was maintained. 
[98] 
 
2014 Retrospective 
study 
Multi center 
141 Allergan Revision of breast 
augmentation (n=40); 
revision of breast 
reconstruction (n=24); 
mastopexy augmentation 
(n=20); mastopexy 
augmentation-revision 
(n=16); hernia repair 
(n=11); other (n=30) 
0 to 12  Adverse side effect reporting 
voluntary. 
Surgeons rated the ease of use a 
mean of 2.86 (scale 0Ð3) 
Surgeons rated their satisfaction a 
mean of 9.31 (scale 0Ð10) 
[99] 
 
2014 Prospective study 
Multi center 
139 Allergan 2-stage implant-based 
breast reconstruction 
6 75 subjects undergone stage 2, 
subject satisfaction score 4.3 ± 0.91 
(5 best). Investigator satisfaction 
score was 9.4± 0.84 (10 best). 
Adverse effects in 214 breasts: tissue 
necrosis (6.1%), seroma (6.1%), 
hematoma (2.8%), breast infection 
(1.9%), cellulitis (1.9%), implant loss 
(1.9%), capsular contracture (0%).  
[100] 
 
2014 Retrospective case 
report 
1 Allergan abdominoplasty and 
lower body lift of in 
patient with massive 
weight loss. Scaffold 
implantation on left 
lower body only. 
7 No complications reported, Improve 
patient satisfaction 
[101] 
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2014 Retrospective case 
report 
1 Allergan brachioplasty 6 No complications reported, perceived 
faster maturation process and a 
better-quality scar 
[102] 
 
2014 Retrospective 
study 
Multi center 
172 Not 
disclosed 
77 patients (71 women, 6 
men) underwent 
abdominal wall fascial 
repair or reinforcement. 
The remaining 95 
patients not reported on. 
18.4 ± 7.5 The overall complication rate (N77) 
was 6.5%, consisting of 2 wound 
dehiscences, 1 with device exposure, 
1 seroma, 1 infection with 
explantation, and a perioperative 
bulge requiring reoperation 
[97] 
 
2014 Retrospective 
study 
Single center 
15 No Direct-to-implant after 
skin-sparing mastectomy 
6 to 13 Capsular contraction (35%); loss of 
scaffold due to necrosis (n=1); 
seroma (n=1); hematoma self-
limiting (n=1); patient satisfaction 
(5.77 out of 10)  
[103] 
 
2015 Correspondence 
Retrospective 
study 
Single center 
5 No Unilateral skin-sparing 
mastectomy and 
immediate 
reconstruction 
Not 
reported  
Late infection (6 weeks and 3.5 
months post-surgery) in 2 breasts 
leading to scaffold and implant 
removal. In 2 patients successful 
completion with tissue integration 
and vascularization. 
[104] 
 
2015 Prospective study 
Multi center 
139 Allergan 71 patients undergoing 
2-stage breast 
reconstruction 
12 Investigator satisfaction score was 
9.4 ± 0.91 (10 best) and patient 
scores was 4.5 ± 0.82 (5 best). 
Complication rates in 105 breasts 
were tissue necrosis (6.7 %), seroma 
(5.7 %), hematoma (4.8 percent), 
implant loss (3.8 %), capsular 
contracture (1.9 %), breast infection 
(1.0%).  
[72] 
 
2015 Correspondence 
Retrospective 
study. Single 
center 
4 No Breast reconstruction 12  Late infection with Ps. aeruginosa in 
2 patients at 5 months resulting in 
implant replacement. Lack of mesh 
integration (or degradation) in all 4 
patients 
[105] 
 
2017 Prospective study 
Multi center 
103 Allergan 2-stage implant-based 
breast reconstruction 
24 Investigator satisfaction high.  
Adverse effects in 161 breasts: 
[106] 
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necrosis and wrinkling (8.1% each) 
and seroma, wound dehiscence, and 
breast redness (5.0% each). Over 2 
years, 4 breasts in 4 subjects 
underwent reoperation with 
explantation of any device; 2 breasts 
required SERI explantation. 
2018 Prospective study 
Single center 
16 No direct-to-implant 
reconstruction with 
surgical scaffold after 
skin-sparing mastectomy 
24 to 37 No intraoperative complications. 
Adverse effects in 22 breasts: 
Postoperative bleeding, that required 
reoperation occurred in 5% breast, 
postoperative seroma in 45% and 
surgical site infection in 9%. 
Scaffold-related complications 
occurred in 14% breasts, lack of 
scaffold integration in all, resulting in 
skin ulceration in 2 and the scaffold 
lying free in the breast pocket 
surrounded with seroma in one. 
[66b] 
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Table 2. Published data reporting the clinical use of silk garments for the treatment of atopic dermatitis in humans  
 
Year Article type Patient 
number 
 Study 
sponsor 
Patients and 
intervention 
Clinical 
follow up  
Reported outcome Reference 
2004 Retrospective 
study 
Single center 
46 ND Children 4 months to 10 
years. DermaSilk¨ 
treatment or cotton 
clothing, topical 
moisturizing cream or 
emulsion. 
1 week Local score of treated and untreated 
area of same child (SCORAD index). 
Overall DermaSilk¨ decreased 
atopic dermatitis severity and local 
improvement of silk treated areas. 
[108c] 
 
2006 Retrospective 
study 
Single center 
15 ND Children 0.6 to 9.2 years, 
body suits made out of 
DermaSilk¨ and cotton 
(50:50). Cotton side also 
received topical 
corticosteroid 
3 weeks Significant improvement of atopic 
dermatitis by assessing eczema area 
and severity (EASI index) 
irrespective of intervention. No 
significant difference between 
DermaSilk¨ and corticosteroid 
treatment. 
[111] 
 
2007 Retrospective 
study 
Single center, 
Randomized, 
single-blinded 
22 ND Children 5 to 12 years 
old. DermaSilk¨, silk 
fabric and cotton. 
Control on contralateral 
arm (silk for first for 2 
weeks followed by 
cotton for rest of study 
period), topical 
moisturizing cream or 
emulsion, antihistamines 
prn 
3 months DermaSilk¨ arm significantly 
improved over study period when 
compared to cotton. Silk control 
treatment showed significant 
improvement of SCORAD index.  
[108b] 
 
2008 Retrospective , 
randomized, 
double-blinded 
30 ND Age 3 to 31 years (mean 
14.2). DermaSilk¨ 
sleeve versus equivalent 
silk only fabric. 
1 month Significant decrease in SCORAD 
index for both groups. Silk only 
fabric rapid reduction over 2 weeks 
only while DermaSilk¨ over 4 
weeks; decrease in pruritus values 
similar during first 2 weeks but 
further decrease for DermaSilk¨ 
group until end of study 
[108d] 
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2013 Retrospective, 
single center, 
double blind 
randomized 
controlled trial 
22 ND Age 4 to 18 months. 
Acute phases treated as 
per international 
guidelines. DermaSilk¨ 
body and tights, or wear 
clothes in pure cotton; 
expect May to 
September  
24 months Significant reduction in topical 
steroid use for DermaSilk¨ group; 
subjective pruritus also reduced 
significantly  
[108a] 
 
2017 Retrospective, 
multi-center  
parallel-group, 
randomised, 
controlled, 
observer-blind 
trial 
300 University of 
Nottingham, 
National 
Institute for 
Health 
Research 
Clinical 
Research 
Network 
Children aged 1 to 15 
years. Standard care or 
standard care plus silk 
garment (either 
DermaSilk¨ or 
DreamSkin¨). Eczema 
outcome and skin 
infections 
24 weeks No statistical difference between 
groups for eczema area and severity 
(EASI index). Less frequent skin 
infections in silk group. Data not 
stratified for different silk garments. 
Included cost-benefit analysis rejects 
garments.  
[108e] 
 
SCORAD: An atopic dermatitis scoring system combining extent, severity, and subjective symptoms  
EASI: Eczema area and severity index 
DermaSilk¨: AL.PRE.TEC. Italy, Silk is covalently functionalized with the antimicrobial 3-trimethylsilylpropyl-dimethyloctadecyl ammonium chloride (AEM 
5700/5772; AEGISª)  
DreamSkin¨: DreamSkin Health Ltd UK. The silk fabric contains zinc-based antimicrobial and is coated with 2-(methacryloyloxy)ethyl-2-(trimethylammonio) 
ethylphosphate-stearylmethacrylate copolymer to from multilayer lamellar structures. The amphiphilic copolymer is proposed to serve as both a barrier and 
moisturizer.  
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Table 3. Reported human clinical trials using silk 
Title Status Number of 
patients 
Study completion 
date 
Study results Primary outcome 
measure 
Identifier 
SeriACLª device trial for 
anterior cruciate ligament 
(ACL) reconstruction 
Unknown. Status 
was active not 
recruiting 
30 October 2008 Not posted Safety - measured by 
device related serious 
adverse events (Time 
frame: 12 months)  
NCT00490594 
Coated VICRYL Plus 
suture compared to Chinese 
silk in scheduled breast 
cancer surgery 
Completed 101 May 2009 Posted Mean score on cosmetic 
outcome visual analog 
scale (Time frame: 30 
days (+/- 5) post-
operative) 
NCT00768222 
Clinical and economic 
outcomes with the use of 
SERI Surgical Scaffold¨ in 
direct-to-implant breast 
reconstruction 
Withdrawn (strategic 
priorities impacted 
study) 
ND August 2014 Not posted Incidence rate of implant 
loss (SERI Surgical 
Scaffold¨ and breast 
implant) (Time frame: 52 
weeks) 
NCT02033590 
Evaluation of HQ¨ Matrix 
medical wound dressing for 
healing of donor site 
wounds 
Completed 71 September 2014 Posted Time to wound healing 
(Time frame: Days 0, 
3±1, 7±1, 10±2, 14±3, 
and 21±3 post-operation) 
NCT01993030 
SERI Surgical Scaffold¨ 
use in reconstruction post 
market study for tissue 
support and repair in breast 
reconstruction surgery in 
Europe 
Completed 100 February 2015 Posted Investigator satisfaction 
following use of SERI 
Surgical Scaffold¨ 
evaluated using an 11-
point scale questionnaire 
(Time frame: Six 
months) 
NCT01389232 
Efficacy and safety of silk 
fibroin with bioactive 
coating layer dressing 
Completed 29 May 2015 Not posted Clinical efficacy of 
wound dressing 
containing silk fibroin 
with a sericin bioactive 
coating layer dressing in 
the treatment of split-
thickness skin graft 
donor sites (Time frame: 
Within 14 days) 
NCT02091076 
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SERI Surgical Scaffold¨ 
postmarket study of soft 
tissue support and repair in 
breast reconstruction 
Completed 17 March 2016 Not posted Incidence of Implant 
Loss (Time frame: 24 
months postoperatively) 
NCT01914653 
A SERI Surgical Scaffold¨ 
postmarket study of soft 
tissue support in ventral 
hernia repair 
Completed 1 June 2016 Not posted Rate of hernia recurrence NCT01981044  
 
Circumferential periareolar 
mastopexy using SERI 
Surgical Scaffold¨ 
Completed 14 June 2016 Not posted Size of the areola at 12 
months as measured by 
physical mammometry 
NCT02293798 
Suture materials: an 
evaluation 
Completed 36 November 2016 Not posted Accumulation of soft 
deposits (Time frame: 7 
to 14 days) 
NCT03410433 
SERI Surgical Scaffold¨ 
Support of the Lower Pole 
of the Breast (SeriSupport) 
Completed 76 November 2016 Posted Nipple to Fold 
Measurement on Stretch 
(Time frame: 1 year post 
op) 
NCT02016612 
Evaluation of HQ¨ Matrix 
soft tissue mesh for the 
treatment of inguinal hernia 
Unknown 144 December 2016 Not posted Postoperative recurrent 
rate (Time frame: Day 1 
post-operation) 
NCT02487628 
The comparison of 
microbial adherence to 
various sutures in patients 
undergoing oral surgery 
Unknown. Status 
was not yet 
recruiting 
30 May 2017 Not posted Bacterial counts on blood 
agar plates from each 
suture will be quantified 
in CFU (colony-forming 
units) and expressed as 
total bacteria/suture 
(Time frame: Outcome 
measure will be assessed 
10 days after sample 
incubation for the 
different sutures obtained 
from each study 
participate) 
NCT02653924 
Initial safety evaluation of 
FibroFixª Meniscus 
Terminated (Safety). 
Devices explanted. 
12 m post-explant 
4 July 2017 Not posted Safety (Time frame: 12 
months) 
NCT02205645 
